Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kinevant Sciences (kine-a-vant) is a clinical-stage biopharmaceutical company dedicated to treating rare inflammatory and autoimmune diseases with significant unmet need. Our lead candidate namilumab is a novel monoclonal antibody being developed for the treatment of pulmonary sarcoidosis. Namilumab targets GM-CSF, a key pro-inflammatory cytokine involved in the pathogenesis of sarcoidosis and other inflammatory disorders.

List your booth number for exhibitions, ask us